Hızlı Erişim

Bu Dergi DOI ve Crosscheck üyesidir



COVID-19 disease caused by the virus called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a highly contagious disease leading to hyperinflammation. Lockdown measures implemented due to COVID-19 can lead to weakness in the calf muscles of the elderly individuals who stay at home for a long time and in those receiving COVID-19 treatment in intensive care unit. Thus, venous insufficiency may develop in these circumstances. It is important to treat these patients without delay, as it may prevent the progression to chronic venous insufficiency. Our study includes eight patients who were diagnosed with COVID-19 and were discharged after being treated in various centers, but later developed venous insufficiency. Two of the patients were women and six were men. Their ages ranged from 43 to 70, and the mean age was 56.87 ± 9.70 years. The main complaints of the patients were pain, swelling, itching, tingling, burning, edema, cramping, feeling of heaviness and discoloration in the legs. D-dimer levels of the patients were also high. Venous insufficiency was diagnosed because reflux was detected in the deep veins of both lower extremities in the color venous Doppler ultrasonographic examination of the patients. Bilateral lower extremity deep veins were patent in all patients. Considering that venous insufficiency may be seen after recovery in COVID-19 patients, intermittent control of these patients should be done after discharge. It is important to closely monitor patients who develop venous insufficiency after COVID-19 treatment, and to strengthen the weakened calf muscles with exercises in addition to medical treatment with venoactive drugs. Since venous insufficiency may regress as a result of the strengthening of calf muscles, it should not be rushed for invasive procedures.

COVID-19, Venous Insufficiency, Calf Muscle Pump

Kaynakça 1. Atıcı Y, Elbaş Y, Bakır F, Yıldırımkaya MM. COVID-19 enfeksiyonunda ACE ve ACE2 reseptörlerinin potansiyel rolü. Yücal D, editör. COVID-19 pandemisinde tıbbi biyokimyanın artan rolü. 1. Baskı. Ankara: Türkye Klinikleri; 2021. P.57-61. 2. Beyaz MI. (2020). Venöz Yetmezlik Etiyolojisinde Kronik İnflamasyon: Epstein Barr Virüs Dna'sı. Sağlık Bilimlerinde Güncel Araştırmalar Cetinje, 83-94. 3. Davoodi L, Jafarpour H, Taghavi M, Razavi A. COVID-19 Presented With Deep Vein Thrombosis: An Unusual Presenting. J Investig Med High Impact Case Rep. 2020 Jan-Dec;8:2324709620931239. doi: 10.1177/2324709620931239. PMID: 32493073; PMCID: PMC7273555. 4. Gürkan S, Gür Ö. COVID-19 hastalığında kalp damar sistemi risk faktörleri ve etkileri. Akgül A, editör. COVID-19 Vaskülopati, Post-COVID-19 fenomeni ve Kalp Damar Cerrahisi 1. Baskı. Ankara: Türkiye Klinikleri;2020. P.1-11. 5. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020 Jul;191:145-147. doi: 10.1016/j.thromres.2020.04.013. Epub 2020 Apr 10. PMID: 32291094; PMCID: PMC7146714. 6. Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020;38(7):1504-1507. doi: 10.1016/j.ajem.2020.04.048. Epub 2020 Apr 18. PMID: 32317203; PMCID: PMC7165109. 7. Nicolaides AN. The Benefits of Micronized Purified Flavonoid Fraction (MPFF) Throughout the Progression of Chronic Venous Disease. Adv Ther. 2020 Feb;37(Suppl 1):1-5. doi: 10.1007/s12325-019-01218-8. Epub 2020 Jan 22. PMID: 31970659; PMCID: PMC7004432. 8. Özdemir ÖÇ, Altındağ E, Avcı F, Uysal MF. Kronik venöz yetmezlik. Turkiye Klinikleri J Health Sci 2016;1(2):125-138. 9. Pothiawala S. Deep vein thrombosis in non-covid-19 patients: an additional risk. Signa Vitae. 2020;16(1):179-181. 10. Schulman S, Hu Y, Konstantinides S. Venous Thromboembolism in COVID-19. Thromb Haemost. 2020;120(12):1642-1653. doi: 10.1055/s-0040-1718532. Epub 2020 Oct 24. PMID: 33099284; PMCID: PMC7869046. 11. Skeik N, Manunga J, Mirza A. Caring for patients with venous insufficiency during the COVID-19 pandemic at a tertiary care center. J Vasc Surg Venous Lymphat Disord. 2020 Jul;8(4):695. doi: 10.1016/j.jvsv.2020.04.023. Epub 2020 May 5. PMID: 32380086; PMCID: PMC7198405. 12. Yasim A. Venoactive drug therapy on treatment of venous ulcer. KSU Med J 2017; 2(3):19-21. 13. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5. PMID: 32139904; PMCID: PMC7095524.

Gelişmiş Arama





    mail mail mail mail mail

    Dergimizin Mayıs sayısı 



    mail mail mail mail mail



    mail mail mail mail mail


    Temmuz Sayısı 

    İçin Makalenizi  

    Sisteme Yükleyebilirsiniz.

    mail mail mail mail mail


Adres :Göztepe Mah., Beykoz, İstanbul/TURKEY
Telefon :+90 555 005 92 85 Faks :+90 216 606 32 75
Eposta :info@euroasiajournal.org

Web Yazılım & Programlama Han Yazılım Bilişim Hizmetleri